Alzheimer's disease

Headband to treat mild and moderate Alzheimer’s disease to be trialled
Clinical Trials Arena
Tue, 08/1/23 - 11:48 am
Alzheimer's disease
Medtech
clinical trials
Electro Cellular Healthcare Solutions
Promising new Alzheimer's drugs may benefit whites more than Blacks
Reuters
Mon, 07/31/23 - 10:04 pm
Alzheimer's disease
racial disparity
After quitting FDA adcomm in protest of Aduhelm decision, Harvard's Aaron Kesselheim finds agency has an approval bias
Fierce Pharma
Mon, 07/31/23 - 10:07 am
FDA
Biogen
Aduhelm
Alzheimer's disease
advisory committees
drug approvals
I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO
Motley Fool
Thu, 07/27/23 - 10:17 am
Biogen
Alzheimer's disease
Pharma CEOs
Chris Viehbacher
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
BioSpace
Mon, 07/24/23 - 09:57 am
neurodegenerative disease
Alzheimer's disease
Axsome Therapeutics
Eli Lilly
Anavex
TauRx
AB Science
ALS
BrainStorm Cell Therapeutics
Seelos Therapeutics
Parkinson's Disease
AbbVie
Mitsubishi Tanabe Pharma
Annovis
Huntington's disease
Prilenia Therapeutics
Neurocrine
After winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous version
Fierce Pharma
Thu, 07/20/23 - 10:09 am
Eisai
Biogen
Leqembi
FDA
Alzheimer's disease
subcutaneous drug delivery
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
Clinical Trials Arena
Wed, 07/19/23 - 10:27 am
Eli Lilly
donanemab
Eisai
Biogen
Leqembi
Alzheimer's disease
AAIC 2023 – Acumen’s new amyloid approach impresses
EP Vantage
Wed, 07/19/23 - 10:15 am
AAIC
Acumen
Alzheimer's disease
ACU193
AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress
BioSpace
Tue, 07/18/23 - 11:55 am
AAIC
Alnylam
RNAi
Alzheimer's disease
ALN-APP
clinical trials
Medicare’s Proposed Coverage for Alzheimer’s Scan Could Be Boon for Eisai/Biogen
BioSpace
Tue, 07/18/23 - 11:36 am
CMS
Alzheimer's disease
Eisai
Biogen
PET scans
Lilly shares full pivotal data on Alzheimer’s drug, revealing how it shapes up against Leqembi
Fierce Biotech
Mon, 07/17/23 - 06:51 pm
Eli Lilly
Alzheimer's disease
clinical trials
FDA
donanemab
Alnylam and Regeneron report updated positive Phase I results of Alzheimer’s drug
Clinical Trials Arena
Mon, 07/17/23 - 08:41 am
Alnylam
clinical trials
ALN-APP
Alzheimer's disease
Why new Alzheimer’s drugs are in for a tepid launch
Medical Marketing and Media
Sun, 07/16/23 - 03:11 pm
Alzheimer's disease
drug launches
Biogen
Eisai
Leqembi
Why Isn't Biogen Stock Soaring After This Major FDA Approval?
Motley Fool
Thu, 07/13/23 - 10:16 am
Biogen
Eisai
Leqembi
Alzheimer's disease
How will the price of Eisai and Biogen's Leqembi impact Medicare? Sen. Sanders wants to know
Fierce Pharma
Wed, 07/12/23 - 11:03 pm
Eisai
Biogen
Leqembi
drug pricing
Medicare
Alzheimer's disease
Eisai's US CEO and Alzheimer's lead Ivan Cheung telegraphs retirement days after Leqembi's full FDA nod
Fierce Pharma
Tue, 07/11/23 - 11:20 pm
Eisai
Alzheimer's disease
Leqembi
Ivan Cheung
BMS makes quickfire bets on neurodegeneration, paying $95M to exercise Evotec, Prothena options
Fierce Biotech
Tue, 07/11/23 - 10:13 am
Bristol Myers Squibb
neurodegenerative disease
Prothena
Alzheimer's disease
Evotec
Leqembi Wins Full FDA Approval as First Anti-Amyloid Antibody for Alzheimer’s
BioSpace
Thu, 07/6/23 - 10:08 pm
Biogen
Eisai
Leqembi
FDA
Alzheimer's disease
Why Shares of Cassava Sciences Are Dropping Wednesday
Motley Fool
Wed, 07/5/23 - 07:01 pm
Cassava Sciences
simufilam
Alzheimer's disease
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
Fri, 06/30/23 - 11:52 am
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
SAGE Therapeutics
zuranolone
postpartum depression
major depressive disorder
Roche
Tecentriq
non-small cell lung cancer
CRISPR Therapeutics
Bluebird Bio
lovo-cel
exa-cel
BrainStorm Cell Therapeutics
NurOwn

Pages